Trial0
Sign inMap the options

Clinical trial · NCT07794670

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

RecruitingPhase 2

Sponsor: NewAmsterdam Pharma

Request access helpRegistry record ↗

We save this real registry record and notify you if its published status changes. Create an account to add profile details that improve future matching.

Summary

A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease

Interventions

  • Obicetrapib 10 mg · DRUG

    once daily 10 mg Obicetrapib tablet

  • Matching placebo tablets · DRUG

    matching placebo tablet

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* participants with preclinical AD

Exclusion Criteria:

* APOE genotype not meeting protocol-defined eligibility criteria

Sites (1)

  • K2 Medical Research, Nashville, Tennessee · Recruiting

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2026-09-28.

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease (NCT07794670) — Trial0